Home

About Caucus

Hearings

Documents

Reports

Speeches

Links

Purpose

The Caucus was created to monitor and encourage the U.S. government and private programs seeking to expand international cooperation against drug abuse and narcotics trafficking, and promote international compliance with narcotics control treaties, including eradication. As a formal organization of the Senate, the Caucus has the status of a standing committee. It has subpoena power and is authorized to take testimony of witnesses and to produce books, records, papers, and documents that it deems necessary. In the past it has dealt with international cooperation, eradication, trafficking, interdiction, border control, drug strategies, assessments of Federal programs, and money laundering issues.

The Caucus has held numerous hearings over the years and has issued a number of reports on U.S. narcotics control policy. The primary responsibilities of the I.N.C.C. have involved monitoring of compliance with international narcotics control treaties and agreements, and oversight of U.S. counter narcotics policy and activities.

 

Establishment

The United States Senate Caucus on International Narcotics Control (also known as the Senate Drug Caucus) was originally called the United States Commission on International Narcotics Control, when it was established on August 16, 1985 by the Foreign Relations Authorization Act for fiscal 1986 and 1987.1

Pursuant to the Legislative Branch Appropriations Act of 1986 (PL 99-151), the name of the Commission was changed to the United States Senate Caucus on International Narcotics Control, effective November 13, 1985. (The House had requested the name change because it would more accurately reflect the membership of the group, given that no House Members were to be appointed to it.)

 

PL 99-93 (99 Stat. 455.).

 Membership

The group's authorizing legislation (PL 99-93) provided that the Commission draw its membership from the Senate and from experts in the private sector.  Specifically, the group was to be composed of 12 members, seven Members of the U.S. Senate appointed by the President of the Senate, and five members from the private sector appointed by the president of the United States.  Four of the seven Senators, including one designated as Chairman, were to be selected from the majority party after consultation with the Majority Leader, and three, including the Member designated as Co-Chairman, were to be selected from the minority party, after consultation with the Minority Leader.  The five Commission members selected from the private sector were to be appointed by the President after consultation with the Members of the appropriate congressional committees.  The appointment of private citizens was discontinued after 1987 in accordance with the group's redesignation as the U.S. Senate Caucus on International Narcotics Control.

 

Current Members of Narcotics Caucus

Senator Dianne Feinstein (D-CA) Chairman

Senator Charles E. Grassley (R-IA) Co-Chairman

Senator Jeff Sessions (R-AL)

Senator Charles Schumer (D-NY)

Senator Sheldon Whitehouse (D-RI)

111th Congress Legislation

 

109th Congress Legislation

S.103 The Combat Meth Act

S.1114 The Clean sports Act

S.2560 The Office of National Drug Control Policy Reauthorization Act

S.1137 Amend Anabolic Steroid Control Act to Include DHEA

S.Res.495 The National Vigil For Lost Promise

S.1960 Integrity In Professional Sports Act

S.529 United States Anti-Doping Agency Act

 

108th Congress Legislation

S .2480 Drug Impaired Driving Research and Prevention Act

S.1780 Anabolic Steroid Control Act

S.1784 Methamphetamine Blister Pack Elimination Act

S.1785 Authorization of National Guard counterdrug schools

S.1837 Combating Money Laundering and Terrorist Financing Act

S.1860 To reauthorize the Office of National Drug Control Policy

S. RES. 263 Honoring the men and women of the DEA

 

Previous Legislation

S.2633 RAVE Act